Last reviewed · How we verify

NCT05016466

GOLD 0 - DLCO 1: A Look Beyond the Obstruction. Is Spirometry Enough for COPD (Chronic Obstructive Pulmonary Disease) Screening?

Status unknown Last updated 23 August 2021
What this trial tests

trial testing Standard Care in COPD, Chronic Obstructive Pulmonary Disease in 236 participants. Status unknown.

Timeline
10 September 2021
Primary endpoint
10 February 2025
31 December 2025

Quick facts

Lead sponsorFundación para la Investigación del Hospital Clínico de Valencia
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment236
Start date10 September 2021
Primary completion10 February 2025
Estimated completion31 December 2025
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Fundación para la Investigación del Hospital Clínico de Valencia

Who can join

Adults 18 to 99, any sex, with COPD, Chronic Obstructive Pulmonary Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter observational prospective study in smokers or ex-smokers with cumulative exposure ≥ 10 a / p (years / pack) with respiratory symptoms and presenting a normal spirometry. The patients who sign the corresponding informed consent, will undergo a DLCO and will be divided into two groups according to the result: * Group I. Patients with DLCO \<80%. * Group II Patients with DLCO≥80%. Both groups will be followed for 5 years.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Standard Care

Trials testing the same drug.

Other Fundación para la Investigación del Hospital Clínico de Valencia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05016466.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing